尽管分析员降级, Merck仍维持2025年的前景。 Merck beats earnings estimates but misses revenue, maintains 2025 outlook despite analyst downgrades.

Merck & Co. (MRK)报告说,第二季度收入为每股2.13美元,超过估计数10美元,但收入为158.1亿美元,略微超出预期。 Merck & Co. (MRK) reported second-quarter earnings of $2.13 per share, exceeding estimates by $0.10, though revenue of $15.81 billion slightly missed expectations. 该公司保持强劲的盈利能力,股本回报率为41.05%,净利润率为25.79%,预计2025年全年EPS为8.87-8.97美元,而分析家预测为9.01美元。 The company maintained strong profitability with a 41.05% return on equity and 25.79% net margin, projecting full-year 2025 EPS of $8.87–8.97, while analysts forecast $9.01. 包括Davidson Trust Co.、Fairman Group LLC和TD资产管理公司在内的机构投资者在本季度减少了其股份。 Institutional investors including Davidson Trust Co., Fairman Group LLC, and TD Asset Management reduced their stakes in the quarter. 股价为84.82美元,市场上限为2 118.6亿美元,P/E比率为13.07,具有协商一致的“稳住”评级和105美元平均价格目标。 The stock, trading at $84.82 with a market cap of $211.86 billion and a P/E ratio of 13.07, has a consensus "Hold" rating and a $105.00 average price target. 一些公司调整了其前景,Wells Fargo将价格目标降至90美元,Morgan Stanley降为98美元,Cantor Fitzgerald将其2026财政年度EPS预测降至9.41美元。 Several firms adjusted their outlooks, with Wells Fargo lowering its price target to $90 and Morgan Stanley to $98, while Cantor Fitzgerald cut its FY2026 EPS forecast to $9.41.